Vinva Investment Management Ltd Cuts Stock Position in Elevance Health, Inc. $ELV

Vinva Investment Management Ltd trimmed its holdings in Elevance Health, Inc. (NYSE:ELV) by 52.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,209 shares of the company’s stock after selling 3,569 shares during the period. Vinva Investment Management Ltd’s holdings in Elevance Health were worth $1,026,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Norges Bank purchased a new stake in shares of Elevance Health during the second quarter worth about $1,148,379,000. Sanders Capital LLC boosted its stake in Elevance Health by 24.7% in the 2nd quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares during the period. Artisan Partners Limited Partnership boosted its stake in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC grew its holdings in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after buying an additional 798,457 shares in the last quarter. Finally, Beutel Goodman & Co Ltd. bought a new stake in shares of Elevance Health during the second quarter valued at approximately $293,141,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Down 3.1%

Elevance Health stock opened at $280.80 on Tuesday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market cap of $61.98 billion, a PE ratio of 11.18, a price-to-earnings-growth ratio of 1.60 and a beta of 0.51. The stock has a 50-day moving average of $343.29 and a two-hundred day moving average of $335.14. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion for the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The company’s revenue was up 9.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $3.84 earnings per share. Elevance Health has set its FY 2026 guidance at 25.500- EPS. On average, research analysts anticipate that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, March 10th. This is a positive change from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is currently 27.23%.

Analyst Upgrades and Downgrades

ELV has been the topic of several research analyst reports. Guggenheim lowered their target price on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Wall Street Zen downgraded shares of Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday, February 8th. Leerink Partners increased their price objective on shares of Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a report on Thursday, January 29th. Robert W. Baird boosted their target price on Elevance Health from $297.00 to $340.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a research note on Thursday, January 29th. Twelve investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $390.55.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.